Palatin Technologies price to book ratio PTN

Market value divided by the book value of the company's net assets, since 2011.

Today, Oct 23, 2026: 1.4×
9-year median: 2.7×
Against its 9-year history: 9th; percentile: 0 is its lowest day, 100 its highest
9-year range: 1.0× to 189×
Peer median: 1.6×

Palatin Technologies' price to book ratio is 1.4× as of Oct 23, 2026.

That is below its 9-year median of 2.7×, lower than on 91% of days in the last 9 years.

Over that time it ranged from 1.0× in Mar 2020 to 189× in Nov 2023.

The median for 3 large drugmakers of a similar size is 1.6×.

Price to book ratio over time

median 2.7×

The dashed line is the 9-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	1.4×	1.3×	75.4×
2025	62.8×	62.8×	117×
2024	8.6×	8.6×	20.4×
2023	178×	1.4×	189×
2022	3.1×	1.5×	5.4×
2021	2.7×	1.6×	3.4×
2020	2.0×	1.0×	2.0×
2019	1.9×	1.8×	18.1×
2018	5.6×	5.4×	30.6×
2017	27.4×	26.8×	31.8×
2016	4.8×	1.6×	5.4×
2015	2.2×	0.9×	4.6×
2014	2.6×	1.6×	3.8×
2013	1.6×	0.7×	1.6×
2012	0.7×	0.7×	15.7×
2011	0.9×	0.9×	1.3×

Against its peers

Companies in Drug Manufacturers - General nearest Palatin Technologies' size, closest first, today.

Company	Price to book ratio
PTNPalatin Technologies	1.4×
ATNMActinium Pharmaceuticals	1.6×
SPROSpero Therapeutics	1.5×
LFVNLifevantage	2.2×
Peer median	1.6×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Palatin Technologies

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.